Table 1.
Baseline data of the study cohort.
| Characteristic | Value | |
|---|---|---|
| Patients, n | 113 | |
| Male, n (%) | 69 (61) | |
| Female, n (%) | 44 (39) | |
| Median age (range), years | 70 (36-88) | |
| Mean age ± SD, years | 68.6 ± 8.58 | |
| Primary tumor | ||
| Colon, n (%) | 89 (79) | |
| Rectum, n (%) | 24 (21) | |
| Node status | ||
| Positive, n (%) | 79 (70) | |
| Negative, n (%) | 34 (30) | |
| Presentation of CLM | ||
| Synchronous, n (%) | 24 (21) | |
| Metachronous, n (%) | 89 (79) | |
| Number of CLM | ||
| Median number (range) | 2.5 (1-5) | |
| Mean number ± SD | 2.7 ± 0.16 | |
| Number of 1-3 CLM, n (%) | 87 (77) | |
| Number of 4-5 CLM, n (%) | 26 (23) | |
| Size of CLM, cm | ||
| Median maximum size (range) | 2.8 (0.6-5.0) | |
| Mean maximum size ± SD | 2.9 ± 0.21 | |
| Maximum size ≤ 3 cm, n (%) | 79 (70) | |
| Maximum size > 3-5 cm, n (%) | 34 (30) | |
| CEA levels before RFA, ng/mL | ||
| Median CEA level (range) | 125.5 (3-1.578) | |
| Mean CEA level ± SD | 81.3 ± 15.6 | |
| CEA ≤ 100, n (%) | 71 (63) | |
| CEA > 100, n (%) | 42 (37) | |
| Main cause of unresectability and/or inoperability | ||
| Expected liver remnant ≤ 30%, n (%) | 19 (17) | |
| Proximity to critical structures, n (%) | 25 (22) | |
| Medical comorbidity, n (%) | 52 (46) | |
| Patients refusal, n (%) | 17 (15) | |
| Systemic therapies before RFA | ||
| Median number of lines (range) | 1.5 (1-3) | |
| Mean number of lines ± SD | 1.5 ± 0.07 | |
| ≥2 lines of systemic therapy, n (%) | 47(41) | |
| 5-Fluorouracile monotherapy, n (%) | 43 (38) | |
| Oxaliplatin-based combination therapy (FOLFOX), n (%) | 75 (66) | |
| Irinotecan-based combination therapy (FOLFIRI), n (%) | 54 (48) | |
| + Bevacizumab, n (%) | 30 (27) | |
| + Cetuximab, n (%) | 8 (7) | |
| Systemic therapies before and after RFA | ||
| Median number of lines (range) | 3 (1-5) | |
| Mean number of lines ± SD | 3.1 ± 0.1 | |
| 5-Fluorouracile monotherapy, n (%) | 76 (67) | |
| Oxaliplatin-based combination therapy (FOLFOX), n (%) | 106 (94) | |
| Irinotecan-based combination therapy (FOLFIRI), n (%) | 107 (95) | |
| + Bevacizumab, n (%) | 63 (56) | |
| + Cetuximab, n (%) | 23 (20) | |
| Response to last line regimen before RFA | ||
| Partial remission, n (%) | 63 (56) | |
| Stable disease, n (%) | 21 (19) | |
| Progressive disease, n (%) | 29 (25) | |
CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; RFA, radiofrequency ablation.